<a href="https://www.fiercebiotech.com/biotech/why-autoimmune-car-t-player-cabaletta-looking-have-durability-its-business-and-therapies" hreflang="en">From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’</a>
Cabaletta Bio is advancing its autologous CD19-directed CAR-T therapy, rese-cel, for treating autoimmune diseases like myositis, with plans to submit for approval in late 2027. The company is exploring the potential to administer CAR-T without the typical chemotherapy preconditioning, aiming for safer and more convenient treatments, while also preparing for a robust launch despite not being the first to market.
Cabaletta Bio's strategy to potentially eliminate chemotherapy preconditioning in CAR-T treatments for autoimmune diseases could significantly enhance patient safety and convenience, providing a competitive edge in the autoimmune CAR-T space. This approach, supported by promising early data, may position Cabaletta ahead of competitors in terms of a two- or three-year lead in exploring preconditioning-free therapies, making it a pivotal point for investment consideration and strategic partnerships.